# Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

> **NCT03742245** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 28 (estimated)

## Conditions studied

- Breast Cancer Metastatic
- Breast Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT03742245
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-11
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742245, "Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT03742245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*